AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3302922 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge interview with explicit and behaviorally oriented instructions, followed by a reassurance call the next day
Number of subjects: 321
Study 3302922 — intervention group
Group type: COMPARATOR
Intervention: Routine discharge instructions
Number of subjects: 321
Study 30823941 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 86
Study 30823941 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 86
Study 27576325 — intervention group
Group type: EXPERIMENTAL
Intervention: High BMI (>30); n=16
Number of subjects: 418
Study 27576325 — intervention group
Group type: EXPERIMENTAL
Intervention: Low BMI (<21.5); n=4
Number of subjects: 418
Study 27576325 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal BMI); n=4
Number of subjects: 418
Study 26040946 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-social partnership intervention programme; duration: 3 months; includes home visits and telephone follow-ups.
Number of subjects: 0
Study 26040946 — intervention group
Group type: COMPARATOR
Intervention: Placebo social calls (customary care group).
Number of subjects: 0
Study 23905646 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous contact lens wear (silicone hydrogel lenses) for one week
Number of subjects: 17
Study 23905646 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements (wearing prescribed eyeglasses for one week)
Number of subjects: 17
Study 22413783 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-assisted laparoscopic colectomy (HALC)
Number of subjects: 60
Study 22413783 — intervention group
Group type: COMPARATOR
Intervention: Total laparoscopic colectomy (TLC)
Number of subjects: 60
Study 18465188 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial Pivot fixed-bearing prosthesis
Number of subjects: 92
Study 18465188 — intervention group
Group type: COMPARATOR
Intervention: PFC Sigma mobile-bearing prosthesis
Number of subjects: 92
Study 17303307 — intervention group
Group type: EXPERIMENTAL
Intervention: ERC guidelines 2005 (group B)
Number of subjects: 60
Study 17303307 — intervention group
Group type: COMPARATOR
Intervention: ERC guidelines 2000 (group A)
Number of subjects: 60
Study 15461010 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected women
Number of subjects: 0
Study 15461010 — intervention group
Group type: EXPERIMENTAL
Intervention: Women in HIV-discordant couples
Number of subjects: 0
Study 15461010 — intervention group
Group type: COMPARATOR
Intervention: Women in other HIV-status couples
Number of subjects: 0
Study 11210867 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine at a dosage of 1 mg/kg per day intravenously for 20 days
Number of subjects: 65
Study 11210867 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 65
Study 11783268 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingkailing injection (QKLI) 120 ml/d
Number of subjects: 400
Study 11783268 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingkailing injection (QKLI) 160 ml/d
Number of subjects: 400
Study 11783268 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingkailing injection (QKLI) 200 ml/d
Number of subjects: 400
Study 11783268 — intervention group
Group type: COMPARATOR
Intervention: Lincomycin 1.8 g/d
Number of subjects: 400
Study 11783268 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingkailing injection (QKLI)
Number of subjects: 400
Study 11783268 — intervention group
Group type: COMPARATOR
Intervention: Lincomycin
Number of subjects: 400
Study 7798099 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound drain removal at 24 hours after total joint arthroplasty
Number of subjects: 0
Study 7798099 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound drains used postoperatively
Number of subjects: 0
Study 2472994 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon and insulin therapy
Number of subjects: 57
Study 2472994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 362955 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (50-150 mg)
Number of subjects: 1734
Study 362955 — intervention group
Group type: COMPARATOR
Intervention: Pyrantel
Number of subjects: 1734
Study 362955 — intervention group
Group type: COMPARATOR
Intervention: Piperazine
Number of subjects: 1734
Study 362955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1734
Study 362955 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 1734
Study 31757095 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine n-3 PUFA (three 1 g capsules containing 460 mg/g EPA and 380 mg/g DHA) for 44 weeks
Number of subjects: 132
Study 31757095 — intervention group
Group type: COMPARATOR
Intervention: Control (olive oil) for 44 weeks
Number of subjects: 132
Study 31757095 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine n-3 PUFA
Number of subjects: 132
Study 28440817 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (800 mg p.o.)
Number of subjects: 78
Study 28440817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 25922903 — intervention group
Group type: COMPARATOR
Intervention: Placebo nitrite cream and placebo citric acid cream applied twice daily
Number of subjects: 299
Study 25922903 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose treatment (sodium nitrite, 3%, with citric acid, 4.5%, creams applied twice daily)
Number of subjects: 299
Study 25922903 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-dose treatment (sodium nitrite, 6%, with citric acid, 9%, creams applied once daily at night, with placebo applied in the morning)
Number of subjects: 299
Study 25922903 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose treatment (sodium nitrite, 6%, with citric acid, 9%, creams applied twice daily)
Number of subjects: 299
Study 24607004 — intervention group
Group type: EXPERIMENTAL
Intervention: High Dose (HD) - 5×10(8) TCID50 of modified vaccinia Ankara
Number of subjects: 90
Study 24607004 — intervention group
Group type: COMPARATOR
Intervention: Standard Dose (SD) - 1×10(8) TCID50 of modified vaccinia Ankara (2 doses)
Number of subjects: 90
Study 22401479 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 42
Study 22401479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 19365118 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental liquid dentifrice (ELD), 1,100 ppm F, pH 7.0
Number of subjects: 2
Study 19365118 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental liquid dentifrice (ELD), 1,100 ppm F, pH 4.5
Number of subjects: 2
Study 19365118 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental liquid dentifrice (ELD), 550 ppm F, pH 4.5
Number of subjects: 2
Study 19365118 — intervention group
Group type: COMPARATOR
Intervention: Commercial toothpaste, 1,100 ppm F, pH 7.0
Number of subjects: 2
Study 18074029 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine 100 mg po bid
Number of subjects: 17
Study 18074029 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg po bid
Number of subjects: 17
Study 18074029 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir carboxylate (metabolite)
Number of subjects: 17
Study 18074029 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of amantadine and oseltamivir
Number of subjects: 17
Study 15576702 — intervention group
Group type: EXPERIMENTAL
Intervention: High fidelity simulation based team training (8 hour intensive experience in an ED simulator with three scenarios of graduated difficulty)
Number of subjects: 0
Study 15576702 — intervention group
Group type: COMPARATOR
Intervention: Didactic training in the Emergency Team Coordination Course (ETCC) with no additional simulation training
Number of subjects: 0
Study 11170731 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport (botulinum neurotoxin type A) diluted to a final concentration of 50 U/ml, low-dose treatment cut by approximately 70%
Number of subjects: 0
Study 11170731 — intervention group
Group type: COMPARATOR
Intervention: Recommended higher doses of Dysport
Number of subjects: 0
Study 10181022 — intervention group
Group type: EXPERIMENTAL
Intervention: Observed fidelity (based on dual observation)
Number of subjects: 37
Study 10181022 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapport (measured during teacher observations)
Number of subjects: 37
Study 10181022 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-implementation interview measures
Number of subjects: 37
Study 10181022 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher self-report questionnaire
Number of subjects: 37
Study 10181022 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation variables (overall)
Number of subjects: 37
Study 8026092 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical aural antibiotic therapy (7-day course)
Number of subjects: 50
Study 8026092 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical aural antibiotic therapy administered by someone other than the patient
Number of subjects: 50
Study 2783481 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation at acupuncture points (30‐Hz current applied to 'spleen 6' and 'liver 3')
Number of subjects: 20
Study 2783481 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition (equipment attached but not activated)
Number of subjects: 20
Study 960794 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee
Number of subjects: 9
Study 960794 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine solution
Number of subjects: 9
Study 960794 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated coffee
Number of subjects: 9
Study 960794 — intervention group
Group type: COMPARATOR
Intervention: Hot water
Number of subjects: 9
Study 31498783 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 μg/kg 10-minutes before induction and 0.5 μg/kg/hour maintenance infusion until end of operation)
Number of subjects: 40
Study 31498783 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 40
Study 31498783 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline of same amount and at same rate)
Number of subjects: 40
Study 26924599 — intervention group
Group type: COMPARATOR
Intervention: Iron + Folic Acid (IFA)
Number of subjects: 1320
Study 26924599 — intervention group
Group type: COMPARATOR
Intervention: Micronutrient Mix (MMN)
Number of subjects: 1320
Study 26924599 — intervention group
Group type: COMPARATOR
Intervention: Small-Quantity Lipid-Based Nutrient Supplements (SQ-LNS)
Number of subjects: 1320
Study 26264648 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive behavior therapy (gCBT)
Number of subjects: 190
Study 23118022 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidopaminergic treatment (aripiprazole, haloperidol, or reserpine)
Number of subjects: 72
Study 23118022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 22153396 — intervention group
Group type: EXPERIMENTAL
Intervention: Strabismus surgery performed for 53 children
Number of subjects: 342
Study 19932779 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 287
Study 19932779 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg
Number of subjects: 287
Study 19932779 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (telmisartan + ramipril)
Number of subjects: 287
Study 19932779 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 287
Study 17684878 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of hyperbaric ropivacaine with 0.1 mg of preservative-free morphine and 0.01 mg fentanyl
Number of subjects: 66
Study 17684878 — intervention group
Group type: COMPARATOR
Intervention: 11.25 mg of hyperbaric bupivacaine with 0.1 mg of preservative-free morphine and 0.01 mg fentanyl
Number of subjects: 66
Study 15616954 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound dressing
Number of subjects: 451
Study 15616954 — intervention group
Group type: COMPARATOR
Intervention: No dressing (exposed wounds)
Number of subjects: 451
Study 11238483 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g protein in the form of very lean beef
Number of subjects: 10
Study 11238483 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 10
Study 9669811 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid chemotherapy (HYB) - CAV/PVP, 3-drug CAV on Day 1 and 2-drug PVP on Day 8, repeated every 4 weeks for up to 6 cycles.
Number of subjects: 129
Study 9669811 — intervention group
Group type: COMPARATOR
Intervention: Sequential chemotherapy (SEQ) - CAV followed by PVP, 3 cycles each every 4 weeks, delivered on Days 1 and 8.
Number of subjects: 129
Study 7950884 — intervention group
Group type: EXPERIMENTAL
Intervention: Education programme for cancer prevention and early detection
Number of subjects: 0
Study 7950884 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 0
Study 3261647 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 468
Study 3261647 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 468
Study 3261647 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (ejection fractions 0.30 to 0.49)
Number of subjects: 468
Study 3261647 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (ejection fractions > 0.69)
Number of subjects: 468
Study 31910451 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical music (Bach and Bushido)
Number of subjects: 24
Study 31910451 — intervention group
Group type: COMPARATOR
Intervention: Traditional training methods
Number of subjects: 24
Study 31665005 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 777
Study 31665005 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic therapies
Number of subjects: 777
Study 31665005 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 777
Study 31665005 — intervention group
Group type: EXPERIMENTAL
Intervention: Localised disease
Number of subjects: 777
Study 31665005 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced disease with no treatment
Number of subjects: 777
Study 30189462 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral strategies (CBS) intervention
Number of subjects: 164
Study 30189462 — intervention group
Group type: COMPARATOR
Intervention: Cancer education recordings (attention-control)
Number of subjects: 164
Study 27225598 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation plus tablet (tablet group)
Number of subjects: 115
Study 27225598 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary rehabilitation only (control group)
Number of subjects: 115
Study 24114194 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release (SR) formulations of ONO-5334
Number of subjects: 0
Study 24114194 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release (SR) tablets of ONO-5334
Number of subjects: 0
Study 22797880 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pregabalin, 75 mg q12 h for five consecutive days starting the night before surgery
Number of subjects: 110
Study 22797880 — intervention group
Group type: COMPARATOR
Intervention: Identical placebos
Number of subjects: 110
Study 19485587 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic Therapy (MST)
Number of subjects: 127
Study 17805093 — intervention group
Group type: EXPERIMENTAL
Intervention: Live high-train low (LH+TL) altitude training at a natural elevation of 2000-2500 m for >or=4 weeks for >or=22 hours per day.
Number of subjects: 0
Study 17805093 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated LH+TL devices (e.g., nitrogen apartments, hypoxic tents, hypoxicator devices)
Number of subjects: 0
Study 15154878 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate 200 mg orally before sleep on dialysis days (3 times per week)
Number of subjects: 18
Study 15154878 — intervention group
Group type: COMPARATOR
Intervention: Control group (no etidronate treatment)
Number of subjects: 18
Study 11666124 — intervention group
Group type: EXPERIMENTAL
Intervention: Total triterpenic fraction of Centella asiatica (TTFCA) 60 mg twice daily for 6 months
Number of subjects: 50
Study 11666124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 11666124 — intervention group
Group type: COMPARATOR
Intervention: No treatment (second control group)
Number of subjects: 50
Study 9678378 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted resection
Number of subjects: 16
Study 9678378 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 16
Study 7990345 — intervention group
Group type: EXPERIMENTAL
Intervention: Induracin, prolonged nicotinic acid
Number of subjects: 31
Study 3058442 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (20 mg before meals and at bedtime for six weeks)
Number of subjects: 16
Study 3058442 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral for six weeks)
Number of subjects: 16
Study 3058442 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 16
Study 3058442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31668393 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) bolus
Number of subjects: 9
Study 31668393 — intervention group
Group type: EXPERIMENTAL
Intervention: GH infusion
Number of subjects: 9
Study 31668393 — intervention group
Group type: COMPARATOR
Intervention: GH-receptor antagonist (pegvisomant)
Number of subjects: 9
Study 31668393 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting (36-hour)
Number of subjects: 9
Study 28937255 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of whey proteins (OWIST)
Number of subjects: 16
Study 28937255 — intervention group
Group type: COMPARATOR
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 16
Study 26525617 — intervention group
Group type: EXPERIMENTAL
Intervention: Low calorie diet therapy (LCDT)
Number of subjects: 22
Study 26525617 — intervention group
Group type: COMPARATOR
Intervention: Standard antihypertensive treatment
Number of subjects: 22
Study 23624884 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal incontinence (FI) experiences in people with IBD
Number of subjects: 3264
Study 23624884 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping strategies for IBD-related FI
Number of subjects: 3264
Study 23624884 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional and psychological impact of IBD-related FI
Number of subjects: 3264
Study 23624884 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to professional support for IBD-related FI
Number of subjects: 3264
Study 21748448 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 100
Study 21748448 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 100
Study 19141576 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg daily (with adjustments to 40 mg or 120 mg as needed)
Number of subjects: 116
Study 19141576 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat treatment
Number of subjects: 116
Study 17583188 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril/Indapamide combination (Per 2 mg/Ind 0.625 mg) for 3-6 months
Number of subjects: 17938
Study 14999211 — intervention group
Group type: EXPERIMENTAL
Intervention: Wiktor stent implantation
Number of subjects: 221
Study 14999211 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 221
Study 11174052 — intervention group
Group type: EXPERIMENTAL
Intervention: riluzole 150 mg
Number of subjects: 9
Study 11174052 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study 9296037 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of malocid-sulfadiazine
Number of subjects: 43
Study 9296037 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin subconjunctivally
Number of subjects: 43
Study 8320004 — intervention group
Group type: EXPERIMENTAL
Intervention: Concept 45 degrees toothbrush with the Bass technique
Number of subjects: 100
Study 8320004 — intervention group
Group type: EXPERIMENTAL
Intervention: Concept 45 degrees toothbrush with the roll technique
Number of subjects: 100
Study 8320004 — intervention group
Group type: COMPARATOR
Intervention: Standard conventional toothbrush with the roll technique
Number of subjects: 100
Study 8320004 — intervention group
Group type: COMPARATOR
Intervention: Standard conventional toothbrush with the Bass technique
Number of subjects: 100
Study 3577821 — intervention group
Group type: COMPARATOR
Intervention: Adenosine 0.07 mg kg‐1 min‐1 following saline
Number of subjects: 8
Study 3577821 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine 0.005 mg kg‐1 min‐1 following dipyridamole
Number of subjects: 8
Study 3577821 — intervention group
Group type: COMPARATOR
Intervention: Adenosine 0.08-0.09 mg kg‐1 min‐1 following saline
Number of subjects: 8
Study 28508330 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided intervention
Number of subjects: 0
Study 28508330 — intervention group
Group type: COMPARATOR
Intervention: Self-Directed
Number of subjects: 0
Study 27317506 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-motivated eHealth lifestyle intervention
Number of subjects: 2972
Study 24045438 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant (FS) spray
Number of subjects: 130
Study 24045438 — intervention group
Group type: COMPARATOR
Intervention: Mechanical stapling (MS)
Number of subjects: 130
Study 23391132 — intervention group
Group type: EXPERIMENTAL
Intervention: Situated Optimal Adherence Intervention Estonia (sOAI Estonia) which includes Next‐Step Counseling (NSC) and Information‐Motivation‐Behavioral Skills (IMB) Model approach.
Number of subjects: 0
Study 23391132 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 0
Study 20884422 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous enoxaparin 0.75 mg/kg
Number of subjects: 876
Study 20884422 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 876
Study 20884422 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous enoxaparin 0.75 mg/kg in patients with ACS
Number of subjects: 876
Study 20884422 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) in patients with ACS
Number of subjects: 876